These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 691678)

  • 21. Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection?
    Hadziyannis SJ; Laras A; Hadziyannis E
    Aliment Pharmacol Ther; 2014 May; 39(10):1250-1. PubMed ID: 24735152
    [No Abstract]   [Full Text] [Related]  

  • 22. Proceedings of an international symposium on anti-viral agents in chronic hepatitis B virus infection. London, U.K., 11-12 November 1985.
    J Hepatol; 1986; 3 Suppl 2():S1-317. PubMed ID: 2439567
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interferon: its effects and clinical application].
    Siegert R
    Internist (Berl); 1978 Dec; 19(12):659-63. PubMed ID: 370046
    [No Abstract]   [Full Text] [Related]  

  • 24. Prospects for the clinical use of exogenous interferon.
    Cantell K
    Med Biol; 1977 Apr; 55(2):69-73. PubMed ID: 194114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antiviral treatment of chronic hepatitis B].
    Bourel M; Brissot P
    Rev Prat; 1987 Apr; 37(23):1353-7. PubMed ID: 2440096
    [No Abstract]   [Full Text] [Related]  

  • 26. Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply.
    Galmozzi E; Viganò M; Lampertico P
    Aliment Pharmacol Ther; 2014 May; 39(10):1251-2. PubMed ID: 24735153
    [No Abstract]   [Full Text] [Related]  

  • 27. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan.
    Kobayashi M; Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Matsuda M; Sato J; Takagi K; Miyakawa Y; Kumada H
    J Med Virol; 2002 Dec; 68(4):522-8. PubMed ID: 12376960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Risks and precautions for the use of lamivudine in patients with chronic hepatitis B virus infection].
    Andreani T; Chazouillères O; Calmus Y; Poupon R
    Gastroenterol Clin Biol; 2002 Jan; 26(1):51-6. PubMed ID: 11938040
    [No Abstract]   [Full Text] [Related]  

  • 29. Interferon and other therapies for hepatitis B and hepatitis C infections.
    Rothstein KD; Munoz SJ
    Clin Lab Med; 1996 Jun; 16(2):465-91. PubMed ID: 8792083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical use of interferon and its inducers].
    Nosik NN; Ershov FI
    Antibiotiki; 1980 Sep; 25(9):695-710. PubMed ID: 6158289
    [No Abstract]   [Full Text] [Related]  

  • 31. [What treatment of chronic hepatitis caused by the hepatitis B virus?].
    Ouzan D
    Gastroenterol Clin Biol; 1988 Nov; 12(11):823-6. PubMed ID: 2464519
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antiviral preparations in the therapy of chronic viral hepatitis].
    Geller LI
    Ter Arkh; 1990; 62(11):15-9. PubMed ID: 1710074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon vs. adenine arabinoside 5'-monophosphate in patients with anti-HBe-positive chronic hepatitis.
    Buti M; Jardi R; Rodriguez-Frias F; Allende H; Cotrina M; Esteban R; Guardia J
    J Med Virol; 1996 Aug; 49(4):325-8. PubMed ID: 8877766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferons in the management of viral hepatitis.
    Zein NN
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current concepts in viral hepatitis.
    Hoofnagle JH
    Arq Gastroenterol; 1979; 16(3):124-32. PubMed ID: 94994
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapy of chronic active hepatitis B (CAHB) with interferons].
    Müller R; Siegert W; Hofschneider HP; Deinhardt F; Frösner G; Korb G; Vido I; Schmidt FW
    Z Gastroenterol Verh; 1982 Apr; 17():105-9. PubMed ID: 6191453
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of chronic hepatitis caused by hepatitis B virus].
    Ouzan D
    Rev Prat; 1990 May; 40(14):1298-300. PubMed ID: 1694296
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon treatment in hepatitis B virus-associated membranous glomerulopathy.
    Kavukçu S; Başdemir G; Eroğlu Y; Türkmen M; Eser F; Büyükgebiz B
    Pediatr Nephrol; 1995 Aug; 9(4):539-40. PubMed ID: 7577424
    [No Abstract]   [Full Text] [Related]  

  • 39. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence.
    Wiegand J; Hasenclever D; Tillmann HL
    Antivir Ther; 2008; 13(2):211-20. PubMed ID: 18505172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The course of HBV overinfection during NANB CAH in treatment with IFN.
    Delmastro B; Mastinu A; Bordino C; Casabianca A; Carnevale G
    Panminerva Med; 1992; 34(3):145-6. PubMed ID: 1283463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.